Autres langues Neuland Laboratories Limited

Actions

NEULANDLAB

INE794A01010

Produits pharmaceutiques

Temps Différé Bombay S.E. 07:27:16 22/09/2026			Varia. 5j.	Varia. 1 janv.
22 792,85 ^INR	+0,85%		+1,20%	+50,05%

15/09	Neuland Laboratories Limited accélère l'expansion de sa production de peptides avec la mise en service d'un module opérationnel et de nouvelles capacités en cours de développement	CI
08/09	Les actions indiennes s'orientent vers une ouverture atone face à la remontée du pétrole et aux risques au Moyen-Orient	RE

Autres langues

15/09	Neuland Laboratories Limited Accelerates Peptide Manufacturing Expansion with Operational Module and Additional Capacity Expansion Underway
08/09	Indian shares on track for muted open as oil climbs on rising Mideast risks
05/08	Neuland Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026
05/08	Neuland Laboratories Limited Executes Corporate Guarantee of INR 400 Million in Favour of Gland Pharma Limited Under Loan License Agreement
05/08	Neuland Laboratories Limited Approves Enhancement of Manufacturing Capacity
25/05	LIR Life Sciences Announces Start of Phase 1 of Transdermal Delivery Development Activities
23/05	LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories
12/05	Neuland Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026
12/05	Neuland Laboratories March-quarter consol profit 2.13 bln rupees
12/05	Neuland Laboratories Limited announces Annual dividend, payable on September 03, 2026
02/04	The Weir Group PLC Announces Board and Committee Changes, Effective April 30, 2026
01/04	Neuland Laboratories appoints Saharsh Davuluri as CEO and managing director
01/04	Neuland Laboratories Ltd Appoints Saharsh Davuluri as Managing Director and Sucheth Davuluri as Executive Vice Chairman, Effective April 1, 2026
01/04	Neuland Laboratories Ltd Announces Chief Executive Officer Changes, Effective April 1, 2026
03/03	Neuland Laboratories Limited Announces Demise of Dr. Christopher M Cimarusti, Non-Executive Non-Independent Director on February 28, 2026
09/02	Neuland Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025
09/02	Neuland Laboratories Dec-quarter consol profit 405.7 million rupees
06/02	LIR Life Sciences Corp. Commences Project Phase 2 Peptide Design Program with Neuland Laboratories
09/01	LIR Life Sciences Corp. Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform
28/11	Neuland Laboratories approves 1.89 billion rupees for new research and development center
07/11	Neuland Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025
06/11	Neuland Laboratories Appoints Ravi Gopinath as Independent Director
23/09/25	Neuland Laboratories says Saharsh Rao Davuluri to be CEO & managing director
31/07/25	Neuland Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025
17/06/25	Neuland Laboratories Says SEBI Issues Administrative Warning For Insider Trading Violation